Fidelis Animal Health Announces Ethiqa XR® Label Expansion

Fidelis Animal Health has received notification from the Food and Drug Administration (FDA) that Ethiqa XR (buprenorphine extended-release injectable suspension) 1.3 mg/mL is now also indexed for the control of post-procedural pain in non-human primates (NHPs). With Ethiqa XR, veterinarians have an FDA-cleared, pharmaceutical grade, CGMP extended-release buprenorphine for use in four species: mice, rats, ferrets, and NHPs.